Live Evaluations
A New Era in Systemics for Psoriasis and Psoriatic Arthritis: Coverage From Skin to Joints: WCH24 Seminar-in-Depth
About
A New Era in Systemics for Psoriasis and Psoriatic Arthritis: Coverage From Skin to Joints
This activity is supported by an educational grant from UCB, Inc.
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the role of IL-17 inhibitors for the management of psoriatic disease
Identify techniques for selecting the ideal IL-17 to individualize care in psoriatic disease
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Ronald Vender, MD, FRCPC
Dermatrials Research Inc & Venderm Consulting
Associate Clinical Professor of Medicine
McMaster University
Hamilton, Canada
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
Advisory Board/Consultant: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant
Grant/Research Support: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant, Dermira
Speaker's Bureau: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant, Dermira
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.